Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Lenalidomide
Related studies linked through entity extraction aliases.
Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE2
A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
- Status
- COMPLETED
- Phase
- PHASE1
Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
"Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL
- Status
- COMPLETED
- Phase
- PHASE2
Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide and Obinutuzumab for Previously Untreated CLL
- Status
- WITHDRAWN
- Phase
- PHASE2
Evaluation of the Immune Restoration Potential Of Lenalidomide
- Status
- WITHDRAWN
- Phase
- PHASE2
Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease
- Status
- TERMINATED
- Phase
- PHASE1
Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients
- Status
- UNKNOWN
- Phase
- PHASE3